10-K/A: Sensei Biotherapeutics Files 10-K/A Amendment
Annual Report Amendment
Sensei Biotherapeutics files an amendment to its 2025 10-K report, primarily to update Item 1. Business section and include revised Section 302 certifications.
Summary
- Sensei Biotherapeutics, Inc. is filing an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The amendment's primary purpose is to revise and replace Part I, Item 1. Business, in response to SEC staff comments.
- Revised Section 302 certifications from the Principal Executive Officer and Principal Financial Officer are included as exhibits.
- No financial statements or other financial information have been included in this amendment.
- The amendment does not update other information from the original filing or reflect events after the original filing date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral; it's a procedural amendment to address SEC comments and does not introduce new financial performance data or strategic shifts.
Future Outlook
The filing does not contain forward-looking statements or guidance as it is an amendment to a previous filing focused on business description and certifications.
Management Comments
- "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
- "The purpose of this Amendment No. 1 is to amend and replace in its entirety Part I, Item 1. Business of the Original Filing in response to comments received from the staff of the SEC."
Industry Context
StockSavvy.ai notes that this filing is procedural, focusing on regulatory compliance and business description updates rather than new financial or strategic disclosures. The core business of Sensei Biotherapeutics, as detailed in the amended section, revolves around clinical-stage biotechnology, specifically the development of multi-node inhibitors for cancer treatment, exemplified by their lead asset PIKTOR.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certification Update | Revised Section 302 certifications filed for Principal Executive Officer and Principal Financial Officer. | 2026-06-02 | Ensures compliance with Sarbanes-Oxley Act requirements for financial reporting accuracy. |
Stakeholder Impact
- Shareholders: The amendment does not provide new financial information, so its direct impact on share price is likely minimal, but it ensures continued regulatory compliance.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Fiscal year ended |
| 2026-02-17 | Acquisition of Faeth Therapeutics completed |
| 2026-02-18 | Form 8-K filed regarding merger agreement and private placement financing |
| 2026-03-23 | Date as of which number of shares outstanding is reported |
| 2026-03-28 | Original Form 10-K filing date |
| 2026-06-02 | Date of Amendment No. 1 filing and revised certifications |
Keywords
Sensei Biotherapeutics, 10-K/A, SEC Filing, Amendment, Sarbanes-Oxley Act, Biotechnology, Clinical Stage
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.